Targeted Oncology - Immunotherapy, Biomarkers, and Cancer …
WEBSep 7, 2013 · In an interview, Jaime Merchan, MD, explained the background and data from a biomarker analysis of the CLEAR trial in advanced renal cell carcinoma. Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
Managing Chemotherapy Toxicities for Improved Patient Outcomes
WEBMar 29, 2021 · In a large majority of patients, even when treating with chemotherapy that is highly emetogenic, nausea and vomiting can be prevented. Options include 5-HT3 receptor antagonists (such as ondansetron), NK-1 receptor antagonists (such as aprepitant), glucocorticoids (such as dexamethasone), and olanzapine, a …
DUO-E Trial Focuses on Treating High-Risk Endometrial Cancer
WEBApr 21, 2022 · Shannon N. Westin, MD, MPH, FACOG, an associate professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery at the University of Texas MD Anderson Cancer Center, discusses the endometrial cancer patient population enrolled in the phase 3 DUO-E trial (NCT04269200). The randomized, multicenter, double-blind ...
Continuing Osimertinib Treatment After Progression Prolongs …
WEBJan 25, 2019 · The investigators said that continuing osimertinib after progression, alone or in conjunction with radiotherapy, may provide prolonged clinical benefit in selected patients. They suggested that further study will be needed, especially given the increasing role for osimertinib in the treatment of EGFR -mutant advanced NSCLC. Reference:
FDA Approves Capmatinib in MET Exon 14+ Metastatic Non-Small …
WEBMay 6, 2020 · The FDA granted approval to capmatinib (Tabrecta) for adult patients with metastatic non–small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test. 1 Capmatinib was previously granted Priority Review by the FDA in February 2020 for this indication based on results from the GEOMETRY ...
Nadofaragene Firadenovec Now Fully Available for BCG …
WEBJan 16, 2024 · The real-world evidence study titled ABLE-41 U.S. (NCT06026332) is evaluating nadofaragene firadenovec and currently enrolling patients. Nadofaragene firadenovec-vncg is now fully available for adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive NMIBC with CIS with or without papillary tumors across the United States. 1.
T-DXd as Second-Line Standard in HER2+ Metastatic Breast …
WEBDec 9, 2021 · Compared with ado-trastuzumab emtansine (T-DM1; Kadcyla) as second-line therapy in patients with HER2-positive metastatic breast cancer across all patients subgroups, including those with and without baseline brain metastases, fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) led to prolonged progression-free survival (PFS) and higher responses, according to findings from an exploratory ...
A Decade of Thyroid Cancer Research Brings Precision Medicine to …
WEBFeb 26, 2021 · A Decade of Thyroid Cancer Research Brings Precision Medicine to the Forefront of Care. February 26, 2021. By Nichole Tucker. Article. The rising prevalence of thyroid cancer and thyroid nodules, especially for differentiated thyroid cancer, has brought into question the management of disease as it is known today.
Participating Practices Commend CMS for OCM Changes
WEBFeb 20, 2019 · The 177 OCM-participating practices are currently enrolling patients for performance period 6 of 9; however, results have only been released up to performance period 2. 1. As of January 2, 2019, all practices were required by CMS to take on the 1-sided risk or upside-only arrangement until the start …
From Then to Now: How Genomic Testing for Cancer Has Expanded
WEBAug 26, 2022 · EGFR testing allowing for matching to EGFR-targeted therapies has led the charge for precision medicine in lung cancer as well as a shift in recommended testing for patients. In 2011, the American Society of Clinical Oncology first recommended that all patients with advanced NSCLC be tested for EGFR before deciding on first-line therapy.12 Since 2004, several generations of EGFR TKIs have been ...